Xenon Pharmaceuticals Inc
Atidarymo kaina
SektoriusSveikatos priežiūra
52.45 0.87
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
51.36
Max
52.48
Pajamos | 3M -102M |
|---|---|
Pelnas, tenkantis vienai akcijai | -1.17 |
Darbuotojai | 358 |
EBITDA | -7.6M -112M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +48.14% upside |
Kitas uždarbis | 2026-08-10 |
|---|
Rinkos kapitalizacija | -597M 5B |
|---|---|
Ankstesnė atidarymo kaina | 51.58 |
Ankstesnė uždarymo kaina | 52.45 |
Naujienos nuotaikos
By Acuity
67%
33%
300 / 342 reitingas Healthcare
Xenon Pharmaceuticals Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
